These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19289522)

  • 1. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
    Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
    Lai MT; Lu M; Felock PJ; Hrin RC; Wang YJ; Yan Y; Munshi S; McGaughey GB; Tynebor RM; Tucker TJ; Williams TM; Grobler JA; Hazuda DJ; McKenna PM; Miller MD
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4812-24. PubMed ID: 20805392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.
    Lu M; Felock PJ; Munshi V; Hrin RC; Wang YJ; Yan Y; Munshi S; McGaughey GB; Gomez R; Anthony NJ; Williams TM; Grobler JA; Hazuda DJ; McKenna PM; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3324-35. PubMed ID: 22391531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Reuman EC; Rhee SY; Holmes SP; Shafer RW
    J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
    Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
    Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
    Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
    J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
    Balamane M; Varghese V; Melikian GL; Fessel WJ; Katzenstein DA; Shafer RW
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4522-4. PubMed ID: 22664973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
    Lai MT; Feng M; Falgueyret JP; Tawa P; Witmer M; DiStefano D; Li Y; Burch J; Sachs N; Lu M; Cauchon E; Campeau LC; Grobler J; Yan Y; Ducharme Y; Côté B; Asante-Appiah E; Hazuda DJ; Miller MD
    Antimicrob Agents Chemother; 2014; 58(3):1652-63. PubMed ID: 24379202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
    Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
    Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
    Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
    Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
    Wildum S; Paulsen D; Thede K; Ruebsamen-Schaeff H; Zimmermann H
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5320-9. PubMed ID: 23959304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
    McCormick AL; Parry CM; Crombe A; Goodall RL; Gupta RK; Kaleebu P; Kityo C; Chirara M; Towers GJ; Pillay D
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1806-9. PubMed ID: 21282419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
    La Regina G; Coluccia A; Silvestri R
    Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Oliveira M; Rajotte D; Bethell R; Wainberg MA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4515-26. PubMed ID: 24867966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.